产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0236-1.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0236-2.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0236-3.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0236-4.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0236-5.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0236-6.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](/Public/upfile/pic/product/cell-line-new.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0236-1.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0236-2.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0236-3.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0236-4.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0236-5.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0236-6.jpg)
![U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/product/cell-line-new.jpg)
产品概述
| 名称 | U-2 OS [U2OS] (人骨肉瘤细胞) (STR鉴定正确) |
| 别称 | U-2 OS; U-2OS; U-2-OS; U2-OS; U20-S; U20S; 2T |
| 背景描述 | U-2 OS细胞(原名2T)是由Ponten·J和Saksela·E在1964年从一名15岁女孩的胫骨中等分化的肉瘤中分离建立的。U-2 OS细胞与WI-38细胞共培养或用抗猴空泡病毒SV40、呼吸道合胞病毒RSV或腺病毒的补体结合试验(CF法)未检测到病毒。U-2 OS细胞表达胰岛素样生长因子I、II(IGF-I、IGF-II)受体和骨肉瘤衍生生长因子(ODGF)。 |
| 种属 | 人 |
| 年龄（性别） | 女 |
| 组织来源 | 骨；骨肉瘤 |
| 生长特性 | 贴壁细胞 |
| 细胞形态 | 上皮细胞样 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 肉瘤细胞 |
| 生物安全等级 | 1 |
| 生长培养基 | McCoy's 5A＋10% FBS＋1% P/S |
| 推荐传代比例 | 1:3-1:4 |
| 推荐换液频率 | 2~3次/周 |
| 倍增时间 | ~25-30 hours |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养条件 | 气相：空气，95%；CO2，5% 温度：37℃ |
| 受体表达情况 | insulin-like growth factor I (IGF-I);insulin-like growth factor II (IGF II) |
| 抗原表达情况 | Blood Type A; Rh+; HLA A2, Aw30, B12, Bw35, B40(+/-) |
| 基因表达情况 | osteosacoma derived growth factor (ODGF), Blood Type A; Rh+; HLA A2, Aw30, B12, Bw35, B40(+/-) |
| 保藏机构 | ATCC; HTB-96 DSMZ; ACC-785 ECACC; 92022711 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 13 D2S1338 20,24 D3S1358 16 D5S818 11 D7S820 11,12 D8S1179 12,14 D13S317 13 D16S539 11,12 D18S51 14 D19S433 15 D21S11 31 FGA 20,21 PentaD 9 PentaE 10,13 TH01 6,9.3 TPOX 11,12 vWA 14,18 D6S1043 11 D12S391 19,20 D2S441 10,14 -
STR鉴定图
-
参考文献
-
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase(2021/08/05)
作者：Ximing Shao, Zhihao Ding, Wenhua Zhou
期刊：Nature Nanotechnology
DOI：10.1038/s41565-021-00952-x
影响因子 ：40.523
引用产品：CL-0016 CL-0101 CL-0103 CL-0150A CL-0150B CL-0236 CL-0238
-
Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor(2022/09/22)
作者：Haoyu Guo, Lutong Wang, Wei Wu
期刊：JOURNAL OF CONTROLLED RELEASE
DOI：10.1016/j.jconrel.2022.09.020
影响因子 ：11.4670
-
MoS2 Quantum Dot@Polyaniline Inorganic–Organic Nanohybrids for in Vivo Dual-Modal Imaging Guided Synergistic Photothermal/Radiation Therapy(2016/09/07)
作者：Jinping Wang, Xiaoxiao Tan, Xiaojuan Pang
期刊：ACS Applied Materials & Interfaces
影响因子 ：10.3830
引用产品：CL-0016 CL-0101 CL-0103 CL-0150A CL-0150B CL-0236 CL-0238
-
lncRNA MELTF-AS1 facilitates osteosarcoma metastasis by modulating MMP14 expression(2021/08/26)
作者：Lei Ding, Taiyuan Liu, Yuan Qu
期刊：Molecular Therapy-Nucleic Acids
DOI：10.1016/j.omtn.2021.08.022
影响因子 ：10.183
-
Targeting visualization of malignant tumor based on the alteration of DWI signal generated by hTERT promoter–driven AQP1 overexpression(2022/01/19)
作者：Liang Zhang, Mingfu Gong, Sheng Lei
期刊：European Journal Of Nuclear Medicine And Molecular Imaging
DOI：10.1007/s00259-022-05684-1
影响因子 ：10.0570
-
Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma(2022/03/17)
作者：Shuhong Liang, Xiaojian Zhang, Jun Li
期刊：Bioengineered
DOI：10.1080/21655979.2022.2040827
影响因子 ：6.8320
-
A ferroptosis-related gene signature associated with immune landscape and therapeutic response in osteosarcoma.(2022/11/11)
作者：Xinxing Wang, Guang Xia, Shilang Xiao, Song Wu, Lina Zhang, Junjie Huang, Wenxiu Zhang, Xu Cao, Image_1.tif, Image_2.tif, Image_3.tif, Image_4.tif, Image_5.tif, Image_6.tif, Image_7.tif, DataSheet_1.csv, DataSheet_2.csv, DataSheet_3.csv, DataSheet_4.
期刊：Frontiers in Oncology
影响因子 ：5.7380
-
Schisandrin B Inhibits Cell Viability and Migration, and Induces Cell Apoptosis by circ_0009112/miR-708-5p Axis Through PI3K/AKT Pathway in Osteosarcoma(2021/12/22)
作者：Bing Wang, Xiaowei Wang, Xing Tong
期刊：Frontiers in Genetics
影响因子 ：4.772
-
Down-regulation of PRR11 affects the proliferation, migration and invasion of osteosarcoma by inhibiting the Wnt/β-catenin pathway(2021/09/13)
作者：Ke Li, Hongtao Yu, Chunbing Zhao
期刊：Journal of Cancer
影响因子 ：4.478
-
PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells(2022/11/08)
作者：Zhengjiang Li, Yan Zhang, Yongkui Li, Shuxing Xing, Shunqiang Li, Jing Lyu, Zhaonan Ban
期刊：Experimental and Therapeutic Medicine
影响因子 ：2.7510
